One of the most surprising stories out of the stock market in recent weeks comes courtesy of a biotech company that not all that long ago committed to major operations in Greensboro but then dropped those plans.
ProKidney Corp., a medical biotech company that specializes in kidney disease treatments, stunned Wall Street recently when its stock price jumped more than 500 percent in a single day. In fact, from the end of June through July 10, shares of ProKidney Corp. shot up 775 percent.
The stock, which had been trading below a dollar a share in recent months, went up in value to over $5 a share at one point. The sudden spike was fueled by promising Phase 2 trial results for rilparencel, an experimental cell therapy aimed at slowing or reversing chronic kidney disease in patients with diabetes…